Compare Stocks: GERN, ALKS, IDYA, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$44.04 -5.7%	$49.15	$26.99 ▼ $55.67	$7.39B	0.31	2.09 million shs	1.43 million shs
GERN Geron	$1.32 -0.4%	$1.46	$1.04 ▼ $2.01	$844.85M	0.61	14.24 million shs	4.85 million shs
IDYA IDEAYA Biosciences	$38.44 -0.4%	$37.67	$25.27 ▼ $42.68	$3.38B	-0.07	1.03 million shs	295,568 shs
LEGN Legend Biotech	$17.65 +0.4%	$20.95	$16.24 ▼ $37.50	$3.42B	0.4	2.45 million shs	1.37 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+1.39%	+1.30%	-5.60%	+3.82%	+67.60%
GERN Geron	+2.33%	-3.65%	-13.73%	+4.76%	+3.94%
IDYA IDEAYA Biosciences	+2.33%	+3.10%	+1.79%	+23.63%	+57.98%
LEGN Legend Biotech	+3.41%	-8.39%	-19.80%	-37.06%	-49.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$44.04 -5.7%	$49.15	$26.99 ▼ $55.67	$7.39B	0.31	2.09 million shs	1.43 million shs
GERN Geron	$1.32 -0.4%	$1.46	$1.04 ▼ $2.01	$844.85M	0.61	14.24 million shs	4.85 million shs
IDYA IDEAYA Biosciences	$38.44 -0.4%	$37.67	$25.27 ▼ $42.68	$3.38B	-0.07	1.03 million shs	295,568 shs
LEGN Legend Biotech	$17.65 +0.4%	$20.95	$16.24 ▼ $37.50	$3.42B	0.4	2.45 million shs	1.37 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+1.39%	+1.30%	-5.60%	+3.82%	+67.60%
GERN Geron	+2.33%	-3.65%	-13.73%	+4.76%	+3.94%
IDYA IDEAYA Biosciences	+2.33%	+3.10%	+1.79%	+23.63%	+57.98%
LEGN Legend Biotech	+3.41%	-8.39%	-19.80%	-37.06%	-49.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.78	Moderate Buy	$54.56	23.90% Upside
GERN Geron	2.20	Hold	$4.00	204.18% Upside
IDYA IDEAYA Biosciences	2.80	Moderate Buy	$52.69	37.07% Upside
LEGN Legend Biotech	2.47	Hold	$53.14	201.18% Upside

Current Analyst Ratings Breakdown

Latest GERN, ALKS, IDYA, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ALKS Alkermes	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/9/2026	IDYA IDEAYA Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$54.00 ➝ $57.00
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	IDYA IDEAYA Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/1/2026	IDYA IDEAYA Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/1/2026	IDYA IDEAYA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$42.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.43	$1.60 per share	27.51	$11.02 per share	4.00
GERN Geron	$183.88M	4.59	N/A	N/A	$0.35 per share	3.76
IDYA IDEAYA Biosciences	$234.13M	14.43	N/A	N/A	$11.67 per share	3.29
LEGN Legend Biotech	$1.27B	2.69	N/A	N/A	$5.43 per share	3.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	115.99	183.49	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	21.92	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.08	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)

Latest GERN, ALKS, IDYA, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
GERN Geron	0.55	6.91	5.16
IDYA IDEAYA Biosciences	N/A	10.45	10.45
LEGN Legend Biotech	N/A	3.04	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
GERN Geron	73.71%
IDYA IDEAYA Biosciences	98.29%
LEGN Legend Biotech	70.89%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
GERN Geron	1.71%
IDYA IDEAYA Biosciences	4.70%
LEGN Legend Biotech	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable

GERN, ALKS, IDYA, and LEGN Headlines

Recent News About These Companies

Legend names Ingrid Zhang as CEO

September 17 at 7:02 PM | thepharmaletter.comT

LEGN’s new CEO from Novartis paves way for buyout speculation

September 15 at 11:34 PM | msn.com

Legend Biotech Appoints Ingrid Zhang as CEO

September 15 at 1:33 PM | finance.yahoo.com

Legend Biotech taps Novartis veteran Zhang as CEO

September 15 at 8:46 AM | reuters.com

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

September 15 at 8:00 AM | globenewswire.com

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

September 15 at 7:30 AM | wsj.com

Tidal Investments LLC Purchases 61,023 Shares of Legend Biotech Corporation Sponsored ADR $LEGN

September 13, 2026 | marketbeat.com

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

Wellington Management Group LLP Acquires New Position in Legend Biotech Corporation Sponsored ADR $LEGN

September 11, 2026 | marketbeat.com

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

September 10, 2026 | globenewswire.com

Squarepoint Ops LLC Raises Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

September 9, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Raiffeisen Bank International AG

September 5, 2026 | marketbeat.com

Legend Biotech's (LEGN) Buy Rating Reiterated at HC Wainwright

September 4, 2026 | marketbeat.com

Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?

September 2, 2026 | finance.yahoo.com

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 1, 2026 | globenewswire.com

Legend Biotech Corporation Sponsored ADR $LEGN is Montanova Capital LLC's 4th Largest Position

September 1, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Hold" from Brokerages

September 1, 2026 | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Trading Up 4.8% - Here's Why

August 31, 2026 | marketbeat.com

Bank of America Corp DE Trims Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

August 31, 2026 | marketbeat.com

Legend Biotech Corporation (LEGN)

August 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GERN, ALKS, IDYA, and LEGN Company Descriptions

Alkermes NASDAQ:ALKS

$44.04 -2.67 (-5.72%)

As of 03:02 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Geron NASDAQ:GERN

$1.32 -0.01 (-0.38%)

As of 03:02 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

IDEAYA Biosciences NASDAQ:IDYA

$38.44 -0.17 (-0.44%)

As of 03:02 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Legend Biotech NASDAQ:LEGN

$17.64 +0.07 (+0.37%)

As of 03:02 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, IDYA, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, IDYA, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, IDYA, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, IDYA, and LEGN Company Descriptions

Alkermes NASDAQ:ALKS

Geron NASDAQ:GERN

IDEAYA Biosciences NASDAQ:IDYA

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, IDYA, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, IDYA, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, IDYA, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, IDYA, and LEGN Company Descriptions

Alkermes NASDAQ:ALKS

Geron NASDAQ:GERN

IDEAYA Biosciences NASDAQ:IDYA

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools